Psyence BioMed Announces Settlement of Shareholder Litigation
Psyence Biomedical has settled a shareholder dispute with Kaos Capital, agreeing to pay US$1.5 million, waive a prior C$75,000...
Veru Reports Q1 FY26 Financial Results & Clinical Progress
Veru plans to initiate a Phase 2b “Plateau” study this quarter testing enobosarm, an oral selective androgen receptor modulator,...
AscellaHealth’s Surging Global Growth With New Leadership
AscellaHealth has expanded its international leadership, elevating Gillian Molloy to general manager of international operations and appointing Alexis Moss...
Avicanna Announces Closing of Non-Brokered Placement
Avicanna has closed a non-brokered private placement totaling C$1.55 million, issuing 7,750,001 units at C$0.20 each. Each unit comprises...
Neuronetics Announces Preliminary Q4, Full Year 2025 Results
Neuronetics posted preliminary, unaudited fourth-quarter 2025 revenue of $41.8 million and full-year revenue of $149.2 million, with positive operating...
Exousia Pro Accelerates Growth with 3rd Telehealth Buy
Exousia Pro has signed a third letter of intent to acquire an established telehealth organization, expanding a roll-up that...
Sanofi Announces Successful Completion of Dynavax Acquisition
Sanofi has completed its acquisition of Dynavax Technologies, adding the marketed adult hepatitis B vaccine Heplisav-B and a Phase...
Day One to Report Q4 and Full-Year 2025 Financial Results
Day One Biopharmaceuticals will host its fourth-quarter and full-year 2025 results call on February 24, 2026, at 4:30 p.m....
Polaryx Announces Key Pre-Clinical Data for Soteria Drug
Polaryx Therapeutics has unveiled late-breaking preclinical data for PLX-200, an oral formulation of gemfibrozil, in a Krabbe disease mouse...
Polyrizon Intends to Secure Profitable Jet Operator Stake
Polyrizon, a preclinical-stage biotech developing intranasal hydrogel “biological mask” technologies, has signed a non-binding memorandum of understanding to acquire...